

# Supplementary Material

## Continuous Subcutaneous Levodopa Delivery for Parkinson's Disease: A Randomized Study

**Supplementary Table 1.** Adjusted Mean (SD) Change from Baseline to Day 27 in PDQ-39 Dimension Scores: mITT Set

<b>PDQ-39 dimension</b>	<b>24-hour infusion (N=19)</b>	<b>14-hour infusion (N=19)</b>	<b>Overall (N=38)</b>
Mobility			
Baseline	37.8 (21.7)	52.4 (23.5)	45.1 (23.5)
Change from baseline at Day 27	-3.8 (26.5)	-9.1 (14.3)	-6.5 (21.0)
Activities of Daily Living			
Baseline	35.3 (21.7)	50.0 (20.6)	42.7 (22.1)
Change from baseline at Day 27	-9.0 (17.5)	-12.5 (16.8)	-10.8 (17.0)
Emotional Well-being			
Baseline	22.6 (17.3)	31.4 (20.8)	27.0 (19.4)
Change from baseline at Day 27	-6.6 (13.1)	2.3 (14.6)	-2.0 (14.4)
Stigma			
Baseline	19.1 (19.1)	32.6 (28.1)	25.8 (24.7)
Change from baseline at Day 27	-3.5 (14.7)	-9.5 (22.2)	-6.6 (18.9)
Social Support			
Baseline	6.8 (8.2)	22.6 (18.1)	14.7 (16.0)
Change from baseline at Day 27	-0.5 (11.3)	-4.2 (17.0)	-2.4 (14.5)
Cognitions			
Baseline	18.4 (15.1)	33.9 (21.0)	26.2 (19.6)
Change from baseline at Day 27	0.0 (17.0)	-2.0 (15.5)	-1.0 (16.0)
Communication			
Baseline	21.1 (13.1)	26.8 (21.6)	23.9 (17.9)
Change from baseline at Day 27	-3.7 (13.5)	-0.9 (12.7)	-2.3 (13.0)
Bodily Discomfort			
Baseline	37.7 (16.5)	44.7 (23.8)	41.2 (20.5)
Change from baseline at Day 27	-11.1 (22.3)	-7.5 (22.9)	-9.2 (22.4)